Ocugenincis A Biopharmaceutical Company Based In Malvernpennsylvaniawith Operations In The United States And Irelandthe Company Focuses On Discoveringdevelopingand Commercializing Gene And Cell Therapiesas Well As Vaccinesto Meet Unmet Medical Needsparticularly In Ophthalmology And Infectious Diseasesocugen Aims To Improve Health Outcomes Globally Through Patient Centric Innovation The Company Is Developing Gene Therapies For Inherited Retinal Diseasesincluding Ocu400 And Ocu410Which Target Specific Genetic Mutations And Conditions Like Dry Age Related Macular Degenerationocugen Is Also Involved In Vaccine Developmentincluding The Collaborative Covaxin Covid 19 Vaccine And Additional Candidates For Covid 19 And Fluadditionallyocugen Is Exploring Cell Therapiessuch As Neocartaimed At Treating Knee Cartilage Defectswith A Market Capitalization Of Approximately $136 45 Million And A Dedicated Team Of About 62 Employeesocugen Is Committed To Advancing Its Innovative Treatment Programs And Addressing Critical Health Challenges
Bio International Convention 2025
United States
16 Jun 2025
1875
| Company Name | Ocugen Inc |
| Country |
United States
|
| Address | 5 Great Valley Pkwy Malvern Pennsylvania 19355 Us |
| Telephone | Login to View |
| Login to View |
